Asia Pacific Glaucoma Treatment Market

ID: MRFR/Pharma/2176-HCR
70 Pages
Vikita Thakur
Last Updated: April 06, 2026
Asia-Pacific Glaucoma Treatment Market Share, Trends And Growth Analysis By Disease Indication (Closed Angle Glaucoma (Cag), Open Angle Glaucoma (Oag), Secondary Glaucoma, Congenital Glaucoma And Other), Drug Class (Prostaglandin Analogs (Pgas), Alpha Agonist, Beta Blockers, Cholinergic Drugs, Carbonic Anhydrase Inhibitors, And Others), Surgery (Laser Iridotomy, Laser Trabeculoplasty, Aqueous Shunt Surgery And Peripheral Iridectomy) And By End Users (Hospitals And Home Users) - Forecast Till 2035
Asia Pacific Glaucoma Treatment Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)5.34%
2024 Market Size$ 1,578.4 Million
2025 Market Size$ 1,662.69 Million
2035 Market Size$ 2,797.6 Million
Key Players
Allergan
Bausch Health
Novartis
Pfizer
Santen Pharmaceutical
Aerie Pharmaceuticals
Trends
  • Rising Prevalence of Glaucoma
  • Technological Advancements in Treatment
  • Regulatory Support for Research and Development
Opportunities
  • Increasing Aging Population
  • Rising Awareness and Education
  • Emerging Market for Telemedicine
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Medical Device, BY Disease Type (USD Million)
      1. 4.1.1 Open angle glaucoma
      2. 4.1.2 Angle closure glaucoma
      3. 4.1.3 Others
    2. 4.2 Medical Device, BY Drug Class (USD Million)
      1. 4.2.1 Prostaglandin analogs
      2. 4.2.2 Beta blockers
      3. 4.2.3 Adrenergic agonists
      4. 4.2.4 Carbonic anhydrase inhibitors
      5. 4.2.5 Others
    3. 4.3 Medical Device, BY Distribution Channel (USD Million)
      1. 4.3.1 Hospital Pharmacy
      2. 4.3.2 Retail Pharmacy
      3. 4.3.3 Online Pharmacy
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Medical Device
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Medical Device
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Allergan (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Bausch Health (CA)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Novartis (CH)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Pfizer (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 Santen Pharmaceutical (JP)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Aerie Pharmaceuticals (US)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 Glaukos Corporation (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Merck & Co. (US)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Horizon Therapeutics (IE)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 APAC MARKET ANALYSIS BY DISEASE TYPE
    3. 6.3 APAC MARKET ANALYSIS BY DRUG CLASS
    4. 6.4 APAC MARKET ANALYSIS BY DISTRIBUTION CHANNEL
    5. 6.5 KEY BUYING CRITERIA OF MEDICAL DEVICE
    6. 6.6 RESEARCH PROCESS OF MRFR
    7. 6.7 DRO ANALYSIS OF MEDICAL DEVICE
    8. 6.8 DRIVERS IMPACT ANALYSIS: MEDICAL DEVICE
    9. 6.9 RESTRAINTS IMPACT ANALYSIS: MEDICAL DEVICE
    10. 6.10 SUPPLY / VALUE CHAIN: MEDICAL DEVICE
    11. 6.11 MEDICAL DEVICE, BY DISEASE TYPE, 2024 (% SHARE)
    12. 6.12 MEDICAL DEVICE, BY DISEASE TYPE, 2024 TO 2035 (USD Million)
    13. 6.13 MEDICAL DEVICE, BY DRUG CLASS, 2024 (% SHARE)
    14. 6.14 MEDICAL DEVICE, BY DRUG CLASS, 2024 TO 2035 (USD Million)
    15. 6.15 MEDICAL DEVICE, BY DISTRIBUTION CHANNEL, 2024 (% SHARE)
    16. 6.16 MEDICAL DEVICE, BY DISTRIBUTION CHANNEL, 2024 TO 2035 (USD Million)
    17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 APAC MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY DISEASE TYPE, 2025-2035 (USD Million)
      2. 7.2.2 BY DRUG CLASS, 2025-2035 (USD Million)
      3. 7.2.3 BY DISTRIBUTION CHANNEL, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

APAC Asia Pacific Glaucoma Treatment Market Segmentation

Asia Pacific Glaucoma Treatment Market By Disease Type (USD Million, 2025-2035)

  • Open angle glaucoma
  • Angle closure glaucoma
  • Others

Asia Pacific Glaucoma Treatment Market By Drug Class (USD Million, 2025-2035)

  • Prostaglandin analogs
  • Beta blockers
  • Adrenergic agonists
  • Carbonic anhydrase inhibitors
  • Others

Asia Pacific Glaucoma Treatment Market By Distribution Channel (USD Million, 2025-2035)

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.